What comes after a successful M&A hunt at Gilead Sciences? A promotion for the executive who sewed up its $11.9 billion deal for Kite Pharma.

In the wake of Hurricane Maria, J&J says the company's Puerto Rico manufacturing plants "fared well," but "intermittent" shortages…

Some generics makers are responding to industrywide pricing pressure by bulking up via M&A. Not Novartis.

iBio, a CDMO that focuses on plant-based biotechnology, said it reached an agreement to support Aethlon Medical with the production of its blood purification…

After stirring up a tribal licensing controversy, Allergan has run into a patent setback with big-selling eye medication Restasis.

Investors are demanding change at top drug distributors after an investigation exposed lax controls and lots of Capitol Hill arm-twisting.

Reckitt Benckiser’s feelings about Pfizer’s OTC unit haven’t changed since the company said it’d be keen to buy it. But its resources have.

FDA reviewers flagged data on cardiovascular benefits—and potential eye risks—posed by Novo Nordisk's semaglutide, up for approval later this year.

Mylan and other generics makers urged a Texas judge to call Allergan's Restasis patent deal with the Saint Regis Mohawk Tribe a "sham."

Shire has hinted that a spinoff of its neuroscience unit may be in the works. But one U.S. hedge fund wants more.